Lubiprostone 136790-76-6

Function of Lubiprostone

Lubiprostone is listed on the US market and is the first chemical constipation treatment drug approved by the US Food and Drug Administration (FDA). It is also the only prescription drug approved to treat chronic idiopathic constipation in Switzerland so far. Compared with other laxatives, it not only has a good therapeutic effect on constipation, but also has a low incidence of drug resistance in long-term application, and also has the advantage of a small dose. Lubiprostone belongs to the prostaglandin class of drugs. Prostaglandins are an important class of endogenous natural products, which have multiple biological activities. Its toxicity to the human body is small, and it can exert various physiological effects when taken in a small amount. Therefore, it has attracted widespread attention in pharmacy, medicine, chemistry and biology. The structure of lubiprostone is mainly an acid with a five-membered aliphatic ring and 20 carbons with two side chains. Among them, the five-membered ring contains multiple chiral carbon atoms and two side chains. These chiral carbon atoms respectively control the configuration of each chiral center, making stereoselective synthesis difficult.